Zobrazeno 1 - 10
of 33
pro vyhledávání: '"David O, Willer"'
Publikováno v:
Expert Review of Vaccines, Vol 23, Iss 1, Pp 196-204 (2024)
Introduction Technological innovations have been instrumental in advancing vaccine design and protective benefit. Improvements in the safety, tolerability, and efficacy/effectiveness profiles have profoundly reduced vaccine-preventable global disease
Externí odkaz:
https://doaj.org/article/6933908c16ac4ca2bebe159186989176
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 11, Pp 4132-4143 (2021)
Immunocompromised (IC) persons are at increased risk for herpes zoster (HZ) and its complications, mainly due to impairment of cell-mediated immunity (CMI). The adjuvanted recombinant zoster vaccine (RZV) demonstrated efficacy against HZ in autologou
Externí odkaz:
https://doaj.org/article/4e3aa43ba5b54c61893201423fd6e997
Publikováno v:
Journal of the National Comprehensive Cancer Network. 20:EPR22-118
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac509a10236638c312a3d9ab1a394e42
https://doi.org/10.6004/jnccn.2021.7254
https://doi.org/10.6004/jnccn.2021.7254
Autor:
Keith M. Sullivan, Francis A. Farraye, Kevin L. Winthrop, David O. Willer, Peter Vink, Fernanda Tavares-Da-Silva
Publikováno v:
Vaccine.
Compared with the general population, older adults with immune senescence and individuals who are immunocompromised (IC) due to disease or immunosuppressive therapy are at increased risk for herpes zoster (HZ) and its associated complications, which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0744a3f2444e9b9ab11bb55b98e5179
https://pubmed.ncbi.nlm.nih.gov/36460534
https://pubmed.ncbi.nlm.nih.gov/36460534
Autor:
Angie K Marsh, Aruna P Ambagala, Catia T Perciani, Justen N Hoffman Russell, Jacqueline K Chan, Michelle Janes, Joseph M Antony, Richard Pilon, Paul Sandstrom, David O Willer, Kelly S MacDonald
Publikováno v:
PLoS ONE, Vol 10, Iss 3, p e0121339 (2015)
Cytomegalovirus (CMV) is a highly species-specific virus that has co-evolved with its host over millions of years and thus restricting cross-species infection. To examine the extent to which host restriction may prevent cross-species research between
Externí odkaz:
https://doaj.org/article/2bd1ef28fc8b42509521de1e58d39bfa
Publikováno v:
Human vaccinesimmunotherapeutics. 17(11)
Immunocompromised (IC) persons are at increased risk for herpes zoster (HZ) and its complications, mainly due to impairment of cell-mediated immunity (CMI). The adjuvanted recombinant zoster vaccine (RZV) demonstrated efficacy against HZ in autologou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f20915fb19fb202ed8ea8d0290de243a
https://pubmed.ncbi.nlm.nih.gov/34190658
https://pubmed.ncbi.nlm.nih.gov/34190658
Autor:
Angie K Marsh, David O Willer, Olena Skokovets, Oluwadamilola H Iwajomo, Jacqueline K Chan, Kelly S MacDonald
Publikováno v:
PLoS ONE, Vol 7, Iss 6, p e40158 (2012)
Human endogenous retrovirus type K (HERV-K) transcripts are upregulated in the plasma of HIV-infected individuals and have been considered as targets for an HIV vaccine. We evaluated cynomolgus macaque endogenous retrovirus (CyERV) mRNA expression by
Externí odkaz:
https://doaj.org/article/ec0ef716509b44fcb0ca64d38fdc2d57
Autor:
Andrea Callegaro, David O Willer, Wivine Burny, Caroline Hervé, Joon Hyung Kim, myron J levin, Toufik Zahaf, Anthony L Cunningham, Arnaud Didierlaurent
Publikováno v:
Open Forum Infectious Diseases
Background RZV (GSK) contains the varicella-zoster virus antigen glycoprotein E (gE) and the adjuvant system AS01B that enhances gE-specific immune responses through stimulating innate immunity. AS01B may contribute to the development of transient lo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05cb43a051cd8141b26156b300055635
http://europepmc.org/articles/PMC8644461
http://europepmc.org/articles/PMC8644461
Autor:
Charles P. Andrews, Myron J. Levin, Tino F. Schwarz, Lily Yin Weckx, Lidia Oostvogels, Covadonga Caso, Anthony L. Cunningham, Won Suk Choi, Angelo Pellegrino, Maria Luisa Rodriguez de la Pinta, Joon Hyung Kim, Tiina Korhonen, Edward M. F. Leung, Peter Eizenberg, Jackson H. Downey, David S.C. Hui, Janet E. McElhaney, Azhar Toma, Lars Rombo, Shelly A. McNeil, Wayne Ghesquiere, Roman Chlibek, Ilkka Seppa, Juan Carlos Tinoco, Silvia Narejos Perez, Daisuke Watanabe, Abiel Mascarenas de Los Santos, David O. Willer, Romulo E Colindres, Jose-Fernando Barba-Gomez, Anitta Ahonen, Anne Schuind, Carles Brotons Cuixart, Ferdinandus de Looze, Tommaso Staniscia, Alexander L. Thompson, Yeo Wilfred, Shinn-Jang Hwang, Iris Gorfinkel, Javier Díez Domingo, Meral Esen, Carla A. Talarico, Eugene Athan, Airi Poder, Johan Berglund, Jan Smetana, Pierre Gervais, Valentine Wascotte, Robert W. Johnson, Thiago Junqueira Avelino-Silva, Hideyuki Ikematsu, Karlis Pauksens, Maria Giuseppina Desole, Toufik Zahaf, Rodrigo Ribeiro dos Santos, Joan Puig Barbera
Publikováno v:
Vaccine. 37(43)
Background Herpes zoster (HZ) risk appears to vary by sex and geographic ancestry/ethnicity. Methods In 2 randomized clinical trials, participants received 2 doses of adjuvanted recombinant zoster vaccine (RZV) or placebo intramuscularly, 2 months ap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15c5902400bff974cc20b7af1945a024
https://pubmed.ncbi.nlm.nih.gov/31537443
https://pubmed.ncbi.nlm.nih.gov/31537443
Publikováno v:
Open Forum Infectious Diseases
Background Immunocompromised (IC) populations are at increased risk of developing herpes zoster (HZ) due to disease- and/or therapy-induced immunosuppression. The adjuvanted recombinant zoster vaccine (RZV) has demonstrated 68.2% efficacy in preventi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cc6d83e0aa1789a202b4b8369e6a966
http://europepmc.org/articles/PMC7776102
http://europepmc.org/articles/PMC7776102